2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2459

Epidemiologic Profile of Erectile Dysfunction in SLE: A Multi-Center Study in Latin American Patients
Abstract Number: 1814

Epidemiology and Microbiology of Pneumonia in Systemic Lupus Erythematosus (SLE)
Abstract Number: 3190

Epidemiology of Polymyalgia Rheumatica 2000-2014: A Population Based Study
Abstract Number: 68

Epigenetic and Expression Analysis of Ankylosing Spondylitis Association Loci Point to Key Cell Types Driving Disease
Abstract Number: 661

Epitope Specificity and End-Organ Susceptibility Dictates Anti-Ro52 Mediated Salivary Gland Dysfunction
Abstract Number: 2665

Epratuzumab Treatment of Patients with Systemic Lupus Erythematosus and Secondary Sjogren’s Syndrome: An Exploratory Analysis of Phase 3 Studies
Abstract Number: 471

Epstein-Barr Virus-Induced Expression of Receptor Activator Nuclear Factor-κb Ligand on B Cells Is Possibly Responsible for Erosive Arthritis in Epstein-Barr Virus-Infected Humanized Nonobese Diabetic/Shi-Scid/γcnull Mice
Abstract Number: 656

ERdj5 Function Is Involved in Inflammatory Manifestations of Sjögren’s Syndrome in the Salivary Glands
Abstract Number: 2458

Erectile Dysfunction in Men with Rheumatic Diseases: A Systematic Review
Abstract Number: 933

Erosion Patterns in Seropositive and Seronegative Rheumatoid Arthritis: A Joint-By-Joint Approach
Abstract Number: 1884

Esophageal Dilation and Interstitial Lung Disease Incidence and Progression in Systemic Sclerosis
Abstract Number: 2016

Esophageal Disease in Systemic Sclerosis: Does Heritability Play a Role?
Abstract Number: 838

Esophageal Dysmotility and Interstitial Lung Disease in Patients with Scleroderma: A Retrospective Study
Abstract Number: 2675

Essdai, Clinessdai and DAS Scoring at Diagnosis of Primary Sjogren Syndrome: Association with the Development of Hematologic and Solid Neoplasias in 1301 Patients
Abstract Number: 1244

Establishing a Case Report Form (CRF) for Systemic Autoimmune Diseases Studies

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].